Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 1
2003 1
2004 1
2007 1
2008 1
2009 1
2010 1
2019 2
2020 6
2021 8
2022 4
2023 4
2024 6
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.
Tsai CJ, Yang JT, Shaverdian N, Patel J, Shepherd AF, Eng J, Guttmann D, Yeh R, Gelblum DY, Namakydoust A, Preeshagul I, Modi S, Seidman A, Traina T, Drullinsky P, Flynn J, Zhang Z, Rimner A, Gillespie EF, Gomez DR, Lee NY, Berger M, Robson ME, Reis-Filho JS, Riaz N, Rudin CM, Powell SN; CURB Study Group. Tsai CJ, et al. Lancet. 2024 Jan 13;403(10422):171-182. doi: 10.1016/S0140-6736(23)01857-3. Epub 2023 Dec 14. Lancet. 2024. PMID: 38104577 Free PMC article. Clinical Trial.
Mesonephric and mesonephric-like adenocarcinomas of gynecologic origin: A single-center experience with molecular characterization, treatment, and oncologic outcomes.
Praiss AM, White C, Iasonos A, Selenica P, Zivanovic O, Chi DS, Abu-Rustum NR, Weigelt B, Aghajanian C, Girshman J, Park KJ, Grisham RN. Praiss AM, et al. Among authors: girshman j. Gynecol Oncol. 2024 Mar;182:32-38. doi: 10.1016/j.ygyno.2024.01.015. Epub 2024 Jan 20. Gynecol Oncol. 2024. PMID: 38246044 Free PMC article.
Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, or endometrioid endometrial cancer.
Andres S, Finch L, Iasonos A, Zhou Q, Girshman J, Chhetri-Long R, Green H, Jang D, O'Cearbhaill R, Kyi C, Cohen S, Friedman C, Makker V, Chi DS, Sonoda Y, Chiang S, Aghajanian C, Weigelt B, Grisham RN. Andres S, et al. Among authors: girshman j. Gynecol Oncol. 2024 Oct;189:30-36. doi: 10.1016/j.ygyno.2024.06.026. Epub 2024 Jul 10. Gynecol Oncol. 2024. PMID: 38991472 Free PMC article. Clinical Trial.
Basket study of oral progesterone antagonist onapristone extended-release in combination with anastrozole in progesterone receptor-positive recurrent adult-type granulosa cell tumor of the ovary.
Finch L, Andres S, Iasonos A, Zhou Q, Girshman J, Chhetri-Long R, Green H, Selenica P, Jang D, O'Cearbhaill RE, Kyi C, Cohen S, Friedman CF, Makker V, Chi DS, Sonoda Y, Chiang S, Aghajanian C, Weigelt B, Grisham RN. Finch L, et al. Among authors: girshman j. Int J Gynecol Cancer. 2025 Jan;35(1):100005. doi: 10.1016/j.ijgc.2024.100005. Epub 2024 Dec 18. Int J Gynecol Cancer. 2025. PMID: 39878266 Clinical Trial.
MET Exon 14-altered Lung Cancers and MET Inhibitor Resistance.
Guo R, Offin M, Brannon AR, Chang J, Chow A, Delasos L, Girshman J, Wilkins O, McCarthy CG, Makhnin A, Falcon C, Scott K, Tian Y, Cecchi F, Hembrough T, Alex D, Shen R, Benayed R, Li BT, Rudin CM, Kris MG, Arcila ME, Rekhtman N, Paik P, Zehir A, Drilon A. Guo R, et al. Among authors: girshman j. Clin Cancer Res. 2021 Feb 1;27(3):799-806. doi: 10.1158/1078-0432.CCR-20-2861. Epub 2020 Nov 10. Clin Cancer Res. 2021. PMID: 33172896 Free PMC article.
32 results